6.
Rapezzi C, Aimo A, Barison A, Emdin M, Porcari A, Linhart A
. Restrictive cardiomyopathy: definition and diagnosis. Eur Heart J. 2022; 43(45):4679-4693.
PMC: 9712030.
DOI: 10.1093/eurheartj/ehac543.
View
7.
Yamamoto K, Nishimura R, Redfield M
. Assessment of mean left atrial pressure from the left ventricular pressure tracing in patients with cardiomyopathies. Am J Cardiol. 1996; 78(1):107-10.
DOI: 10.1016/s0002-9149(96)00238-x.
View
8.
Riccardi M, Pagnesi M, Sciatti E, Lombardi C, Inciardi R, Metra M
. Combined pre- and post-capillary pulmonary hypertension in left heart disease. Heart Fail Rev. 2022; 28(1):137-148.
DOI: 10.1007/s10741-022-10251-9.
View
9.
Garcia M
. Constrictive Pericarditis Versus Restrictive Cardiomyopathy?. J Am Coll Cardiol. 2016; 67(17):2061-76.
DOI: 10.1016/j.jacc.2016.01.076.
View
10.
Geske J, Anavekar N, Nishimura R, Oh J, Gersh B
. Differentiation of Constriction and Restriction: Complex Cardiovascular Hemodynamics. J Am Coll Cardiol. 2016; 68(21):2329-2347.
DOI: 10.1016/j.jacc.2016.08.050.
View
11.
Maron B, Rowin E, Maron M
. Hypertrophic Cardiomyopathy: New Concepts and Therapies. Annu Rev Med. 2022; 73:363-375.
DOI: 10.1146/annurev-med-042220-021539.
View
12.
Sandoval Y, Nicholas Burke M, Lobo A, Lips D, Seto A, Chavez I
. Contemporary Arterial Access in the Cardiac Catheterization Laboratory. JACC Cardiovasc Interv. 2017; 10(22):2233-2241.
DOI: 10.1016/j.jcin.2017.08.058.
View
13.
Gotsman M, Lewis B
. Left ventricular volumes and compliance in hypertrophic cardiomyopathy. Chest. 1974; 66(5):498-505.
DOI: 10.1378/chest.66.5.498.
View
14.
Maurer M, Kale P, Fontana M, Berk J, Grogan M, Gustafsson F
. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023; 389(17):1553-1565.
PMC: 10757426.
DOI: 10.1056/NEJMoa2300757.
View
15.
Nagueh S, Smiseth O, Appleton C, Byrd 3rd B, Dokainish H, Edvardsen T
. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29(4):277-314.
DOI: 10.1016/j.echo.2016.01.011.
View
16.
Siontis K, Geske J, Ong K, Nishimura R, Ommen S, Gersh B
. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc. 2014; 3(3):e001002.
PMC: 4309084.
DOI: 10.1161/JAHA.114.001002.
View
17.
Tong X, Shen L, Zhou X, Wang Y, Chang S, Lu S
. Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis. Drugs R D. 2023; 23(3):197-210.
PMC: 10439079.
DOI: 10.1007/s40268-023-00435-5.
View
18.
Nikolaidis L, Doverspike A, Huerbin R, Hentosz T, Shannon R
. Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Circulation. 2002; 105(23):2785-90.
DOI: 10.1161/01.cir.0000017433.90061.2e.
View
19.
Nistri S, Olivotto I, Maron M, Ferrantini C, Coppini R, Grifoni C
. β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012; 110(5):715-9.
DOI: 10.1016/j.amjcard.2012.04.051.
View
20.
Rowin E, Hausvater A, Link M, Abt P, Gionfriddo W, Wang W
. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017; 136(25):2420-2436.
DOI: 10.1161/CIRCULATIONAHA.117.029267.
View